利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

140 条记录 (耗时 0.044 秒)

    Recombinant human anti-FB5 antibodies
    72.
    发明授权
    Recombinant human anti-FB5 antibodies 失效
    重组人抗FB5抗体

    公开(公告)号：US6090930A

    公开(公告)日：2000-07-18

    申请号：US013872

    申请日：1998-01-27

    申请人： Thomas Paul Wallace ,  Francis Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    发明人： Thomas Paul Wallace ,  Francis Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    IPC分类号： C07K16/30 ,  C12N15/13 ,  C07H21/04 ,  C12N1/20

    CPC分类号： C07K16/30 ,  C07K2317/24 ,  C07K2319/00

    摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

    摘要翻译： 本发明提供了针对抗原FB5特异的几种人源化鼠抗体的产生，其被鼠抗体FB5识别。 FB5抗原在广泛恶性肿瘤的血管内皮细胞的腔表面上表达。 本发明还提供编码人源化FB5特异性抗体的许多多核苷酸，用于产生人源化FB5特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。 本发明还提供使用人源化FB5特异性抗体检测癌细胞（体外和体内）的方法。 另外，本发明提供了使用FB5特异性抗体治疗癌症的方法。

    Method for determining oncogenic activity of a substance
    73.
    发明授权
    Method for determining oncogenic activity of a substance 失效
    确定物质致癌活性的方法

    公开(公告)号：US06063359A

    公开(公告)日：2000-05-16

    申请号：US938295

    申请日：1997-09-26

    申请人： Robert Schreiber ,  Lloyd J. Old

    发明人： Robert Schreiber ,  Lloyd J. Old

    IPC分类号： A61K49/00 ,  C12N5/00

    CPC分类号： A61K49/0008

    摘要： A method for screening substances for oncogenic activity is disclosed. The method involves administering the substance to an animal lacking responsiveness to interferon.gamma. and detecting a higher frequency or earlier time of tumor formation in the test animal compared to control animals. In addition, a method is provided for predicting the aggressiveness of a tumor in a patient.

    摘要翻译： 公开了用于筛选致癌活性物质的方法。 该方法包括将物质施用于与对照动物相比，对干扰素γ不敏感的动物和检测动物中较高频率或更早的肿瘤形成时间。 此外，提供了一种用于预测患者肿瘤侵袭性的方法。

    Blood group antigen panel
    77.
    发明授权
    Blood group antigen panel 失效
    血型抗原组

    公开(公告)号：US5168043A

    公开(公告)日：1992-12-01

    申请号：US330591

    申请日：1989-03-28

    申请人： Carlos Cordon-Cardo ,  Kenneth O. Lloyd ,  Connie L. Finstad ,  Lloyd J. Old ,  Mryon R. Melamed ,  Joel Sheinfeld

    发明人： Carlos Cordon-Cardo ,  Kenneth O. Lloyd ,  Connie L. Finstad ,  Lloyd J. Old ,  Mryon R. Melamed ,  Joel Sheinfeld

    IPC分类号： C07K16/30 ,  C07K16/34

    CPC分类号： C07K16/30 ,  C07K16/34 ,  Y10S435/96 ,  Y10S436/811 ,  Y10S436/813

    摘要： The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewis.sup.a or Lewis.sup.b antigens, the presence of the Lewis.sup.a antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewis.sup.b antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor. The invention provides a method of determining whether a human female subject is susceptible to urogenital infection which comprises determining whether the subject is a secretor according to the hereinabove-described methods, a secretor being susceptible to such an infection. The present application also provides a method of disstinguishing urothelial carcinoma from normal tissue, and identifying human germ cell tumor as seminoma or nonseminoma. Finally, the invention provides a panel comprising some or all of the monoclonal antibodies H 29-36 (ATCC No. HB 8248), S8 (ATCC No. HB 9036), T 174 (ATCC No. HB 8242), T 218 (ATCC No. HB 8249), P 12 (ATCC No. HB 8551), F 3 (ATCC No. HB 8217), and K 21 (ATCC No. HB 8549).

    摘要翻译： 本发明描述了一种确定个体的分泌状态的方法，其包括从个体获得生物流体的样品，并确定样品是否包含Lewisa或Lewisb抗原，样本中Lewisa抗原的存在表明 个体是不分泌者，样本中Lewisb抗原的存在表明个体是分泌体，并且不存在表示个体分泌体状态的抗原是不确定的。 本发明还提供了一种进一步确定具有不确定分泌状态的个体的分泌状态的方法，其包括确定来自个体的生物流体样品是否包含A，B或前体1型链抗原，任何此类抗原存在于 样本表明个体是分泌体，样本中缺少任何这样的抗原，表明个体是非分泌者。 本发明提供了一种确定人类雌性受试者是否易于感染泌尿生殖器感染的方法，其包括根据上述方法确定受试者是否是分泌器，分泌器对这种感染敏感。 本申请还提供了一种从正常组织中分离尿路上皮癌的方法，并将人类生殖细胞肿瘤鉴定为精原细胞瘤或非神经瘤。 最后，本发明提供了包含部分或全部单克隆抗体H29-36（ATCC No.BB8248），S8（ATCC No.HB9036），T174（ATCC No.BB8242），T1818（ATCC No.BB8249），P12（ATCC No.HB8551），F3（ATCC No.HB8217）和K21（ATCC No.HB8549）。

    Method for production of monoclonal antibodies for cancer diagnosis and therapy
    78.
    发明授权
    Method for production of monoclonal antibodies for cancer diagnosis and therapy 失效
    生产用于癌症诊断和治疗的单克隆抗体的方法

    公开(公告)号：US5143843A

    公开(公告)日：1992-09-01

    申请号：US732724

    申请日：1991-07-18

    申请人： M. Jules Mattes ,  Lloyd J. Old ,  Kenneth O. Lloyd

    发明人： M. Jules Mattes ,  Lloyd J. Old ,  Kenneth O. Lloyd

    IPC分类号： A61K38/00 ,  C07K16/30 ,  C12N5/20

    CPC分类号： C07K16/30 ,  A61K38/00

    摘要： Monoclonal antibodies to human antigens present on a majority of human cells are described. These mAbs have use in a method for isolating mAb for less expressive antigens, such as cancer antigens, or other antigens associated with particular abnormalities, disorders or disease state. The latter mAbs may be weaker than or not present to such an extent as the first mentioned mAbs. For example, these less expressive mAbs would be useful for cancer diagnosis, especially in the early stages, and for cancer treatment as well where the cancer cell is the target cell for the mAb. The mAb can be tagged with a tissue destructive agent such as a radio-label, a toxin, a chemical poisen, and the like. Some of the mAbs described, subset tumors of particular types and so are useful for tumor subclassification. The mAbs described are also useful in analyzing the properties and functions of their respective antigens in human cells.

    摘要翻译： 描述存在于大多数人细胞上的人抗原的单克隆抗体。 这些mAb用于分离用于较少表达性抗原（例如癌症抗原）或与特定异常，病症或疾病状态相关的其它抗原的mAb的方法。 后一种mAb可能弱于或不存在至如前述mAb的程度。 例如，这些较少表达的mAb可用于癌症诊断，特别是在早期阶段以及用于癌症治疗以及其中癌细胞是mAb的靶细胞。 mAb可以用组织破坏剂如放射标签，毒素，化学品等标记。 描述的一些mAb，特定类型的子集，因此可用于肿瘤分类。 所述的mAb也可用于分析其各自抗原在人细胞中的性质和功能。